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Redox-Sensitive Liposomes for Glioblastoma Treatment
Mette A. Lund, Martin Bak, Nazila Kamaly, Thomas L. Andresen
Technical University of Denmark, DTU Nanotech, Center for Nanomedicine and
Theranistics, Building 423, 2800 Kgs. Lyngby, Denmark
Hypothesis/aim: Treatment of glioblastoma remains a challenge due to inability of the
drug to reach the intracellular target. Invasive glioblastoma is associated with high
grade vascularization and break-down of the blood-brain barrier (BBB), which could
aid in delivering drugs to the tumor site. However, once at the tumor site, the drug
has to be internalized and transported to the specific target. The aim of the current
project is to develop a drug delivery system (DDS) that crosses the permeable BBB to
specifically target invasive glioblastoma cells and thereby facilitate uptake.
Furthermore the DDS will be intracellularly activated to escape the endosome and
drug efflux mechanism, thereby transporting the drug to the intracellular target. The
DDS consists of a positively charged unsaturated liposome formulation,
redox-sensitive lipopeptides with a PEG-linker that shields the positive charge, and a
cell-penetrating or targeting moiety. Doxorubicin is encapsulated within the liposome
lumen.
Methods: Redox-sensitive liposomes are prepared by post-insertion of lipopeptides
containing a disulphide bridge into positively charged liposomes. Reduction of the
disulphide is confirmed by HPLC and zeta-potential (charge-reversal) measurements.
Uptake in U87 cells is confirmed by flow cytometry. Toxicity of the liposomes is
investigated by MTS assay. Intracellular transport and distribution is investigated by
confocal microscopy.
Results: Cleavage and charge-reversal has been confirmed for two different
formulations. Uptake experiments show that the DDS is indeed taken up by
glioblastoma cells when a cell penetrating moiety is included in the formulation.
Furthermore, uptake is confirmed upon activation (charge-reversal) by cleavage of
the disulphide bridge.
